CAR-T细胞治疗自身免疫性疾病的研究述评
王雪懿, 李本尚

Review of CAR-T cell therapy for autoimmune diseases
WANG Xueyi, LI Benshang
表3 CAR-T细胞治疗AID的相关不良反应
Tab 3 Adverse reactions related to CAR-T cell therapy for AIDs
DiseaseCo-stimulatory moleculeSample size/nCRSICANS/n (%)Hematologic toxicity/n (%)

Infection/

n (%)

Reference
Incidence/n (%)GradeDuration/d
SLE4-1BB10 (0)——0 (0)0 (0)UTI: 1 (100)[17]
4-1BB53 (60)Grade 1

Median:

2 (2‒3)

0 (0)0 (0)

URTI: 3 (60).

Otitis: 1 (20)

[18]
CD2830 (0)——0 (0)

Thrombocytopenia:

1 (33)

URTI: 1 (33)[45]

CD28 (anti-BCMA),

4-1BB (anti-CD19)

109 (90)<grade 3Not reported0 (0)

Leucopenia: 5 (50).

Neutropenia: 4 (40).

Anemia: 5 (50).

Lymphocytopenia:

4 (40)

COVID-19 infection: 8 (80).

UTI: 1 (10)

[46]
ASS4-1BB11 (100)Grade 130 (0)0 (0)Enteritis: 1 (100)[24]
4-1BB11 (100)Grade 1Not reported1 (100)0 (0)Herpes simplex: 1 (100)[25]
4-1BB11 (100)Grade 170 (0)0 (0)0 (0)[26]
SSc4-1BB11 (100)Grade 110 (0)0 (0)0 (0)[47]
4-1 BB32 (67)Grade 1

Median:

5 (2‒7)

0 (0)0 (0)

Cellulitis:

1 (33).

URTI: 1 (33)

[48]
CD28 & 4-1BB11 (100)Grade 1Not reported0 (0)0 (0)0 (0)[49]
CD2820 (0)——0 (0)0 (0)0 (0)[50]
MSCD2821 (50)Grade 160 (0)0 (0)0 (0)[51]
NMOSD4-1BB1212 (100)

Grade 1: 11.

Grade 2: 1

Median:

3.5 (1‒8)

0 (0)

Leukopenia: 12 (100).

Neutropenia: 12 (100).

Anemia: 6 (50).

Lymphocytopenia:

12 (100).

Thrombocytopenia:

3 (25)

7 (58)[52]
MGUnknown140 (0)——0 (0)0 (0)0 (0)[53]
CD2822 (100)

Grade 1: 1.

Grade 2: 1

Patient 1: 10.

Patient 2: 9

1 (50)0 (0)

Tooth pulpitis:

1 (50)

[54]
MMNCD2811 (100)Grade 231 (100)Neutropenia: 1 (100)0 (0)[55]